[HTML][HTML] CDC clinical practice guideline for prescribing opioids for pain—United States, 2022
D Dowell - MMWR. Recommendations and reports, 2022 - cdc.gov
This guideline provides recommendations for clinicians providing pain care, including those
prescribing opioids, for outpatients aged≥ 18 years. It updates the CDC Guideline for …
prescribing opioids, for outpatients aged≥ 18 years. It updates the CDC Guideline for …
Buprenorphine initiation strategies for opioid use disorder and pain management: a systematic review
LA Spreen, EN Dittmar, KC Quirk… - … : The Journal of Human …, 2022 - Wiley Online Library
Buprenorphine possesses many unique attributes that make it a practical agent for adults
and adolescents with opioid use disorder (OUD) and/or acute or chronic pain. Sublingual …
and adolescents with opioid use disorder (OUD) and/or acute or chronic pain. Sublingual …
Treating perioperative and acute pain in patients on buprenorphine: narrative literature review and practice recommendations
M Buresh, J Ratner, A Zgierska, V Gordin… - Journal of general …, 2020 - Springer
Opioid use disorder (OUD), a leading cause of morbidity and mortality in the USA, can be
effectively treated with buprenorphine. However, the same pharmacologic properties (eg …
effectively treated with buprenorphine. However, the same pharmacologic properties (eg …
Safety and preliminary outcomes of short-acting opioid agonist treatment (sOAT) for hospitalized patients with opioid use disorder
AP Thakrar, TJ Uritsky, C Christopher… - Addiction Science & …, 2023 - Springer
Background Patients with opioid use disorder (OUD) frequently leave the hospital as patient
directed discharges (PDDs) because of untreated withdrawal and pain. Short-acting opioids …
directed discharges (PDDs) because of untreated withdrawal and pain. Short-acting opioids …
Duration of medication treatment for opioid‐use disorder and risk of overdose among Medicaid enrollees in 11 states: a retrospective cohort study
Background and aims Medication for opioid use disorder (MOUD) reduces harms
associated with opioid use disorder (OUD), including risk of overdose. Understanding how …
associated with opioid use disorder (OUD), including risk of overdose. Understanding how …
Buprenorphine dispensing among youth aged≤ 19 years in the United States: 2015–2020
A Terranella, GP Guy Jr, C Mikosz - Pediatrics, 2023 - publications.aap.org
BACKGROUND AND OBJECTIVES Opioid related overdose among adolescents and young
adults in the United States is rising. Medications for opioid use disorder (MOUD), including …
adults in the United States is rising. Medications for opioid use disorder (MOUD), including …
Do out-of-pocket costs influence retention and adherence to medications for opioid use disorder?
C Dunphy, C Peterson, K Zhang, CM Jones - Drug and alcohol …, 2021 - Elsevier
Background Availability of medications for opioid use disorder (MOUD) has increased
during the past two decades but treatment retention and adherence remain low. This study …
during the past two decades but treatment retention and adherence remain low. This study …
A review of pregnancy-induced changes in opioid pharmacokinetics, placental transfer, and fetal exposure: Towards fetomaternal physiologically-based …
MW van Hoogdalem, SL Wexelblatt, HT Akinbi… - Pharmacology & …, 2022 - Elsevier
Physiologically-based pharmacokinetic (PBPK) modeling has emerged as a useful tool to
study pharmacokinetics (PK) in special populations, such as pregnant women, fetuses, and …
study pharmacokinetics (PK) in special populations, such as pregnant women, fetuses, and …
Comparing rapid micro-induction and standard induction of buprenorphine/naloxone for treatment of opioid use disorder: protocol for an open-label, parallel-group …
JSH Wong, M Nikoo, JN Westenberg, JG Suen… - Addiction Science & …, 2021 - Springer
Abstract Background Buprenorphine/naloxone (Suboxone) is a current first-line treatment for
opioid use disorder (OUD). The standard induction method of buprenorphine/naloxone …
opioid use disorder (OUD). The standard induction method of buprenorphine/naloxone …
Patient-centered quality measurement for opioid use disorder: Development of a taxonomy to address gaps in research and practice
AT Kelley, MA Incze, JD Baylis, SG Calder… - Substance …, 2022 - journals.sagepub.com
Background: Evidence-based treatment is provided infrequently and inconsistently to
patients with opioid use disorder (OUD). Treatment guidelines call for high-quality, patient …
patients with opioid use disorder (OUD). Treatment guidelines call for high-quality, patient …